News & Publications

KemPharm® is a clinical stage, specialty pharmaceutical company engaged in the development and discovery of proprietary prodrugs that are designed to be improved versions of widely prescribed and FDA approved products.

  • 09

    Jun

    21

  • KemPharm to be Added to Russell 2000® and Russell 3000® Indexes Effective June 28, 2021

  • 03

    Jun

    21

  • KemPharm Executives to Participate in Panel Discussions During Upcoming June 2021 Conferences

  • 26

    May

    21

  • KemPharm, Inc. Announces Orange Book Listing for Six Patents Covering Serdexmethylphenidate (SDX) and Confirmation of NCE Status

  • 13

    May

    21

  • KemPharm Reports First Quarter 2021 Financial Results

  • 07

    May

    21

  • KemPharm Announces Serdexmethylphenidate (SDX) Has Been Classified as a Schedule IV Controlled Substance by the DEA

  • 06

    May

    21

  • KemPharm to Report First Quarter 2021 Results

  • 21

    Apr

    21

  • KemPharm Confirms Receipt of $10 Million Milestone Payment for FDA Approval of AZSTARYS™ Per License Agreement with Affiliate of Gurnet Point Capital

  • 08

    Apr

    21

  • KemPharm Announces Amendment to Licensing Agreement with Gurnet Point Capital Affiliate Following FDA Approval of AZSTARYS™

  • 11

    Mar

    21

  • KemPharm Reports Fourth Quarter and Full-Year 2020 Financial Results

  • 09

    Mar

    21

  • KemPharm to Report Fourth Quarter and Full Year 2020 Financial Results

  • 04

    Mar

    21

  • KemPharm to Present at the 33rd Annual Roth Conference

  • 03

    Mar

    21

  • KemPharm Announces FDA Approval of AZSTARYS™ (serdexmethylphenidate and dexmethylphenidate capsules, for oral use, CII), A New Once-Daily Treatment for ADHD